PT  - JOURNAL ARTICLE
AU  - Nicolò Gozzi
AU  - Matteo Chinazzi
AU  - Jessica T. Davis
AU  - Kunpeng Mu
AU  - Ana Pastore y Piontti
AU  - Marco Ajelli
AU  - Nicola Perra
AU  - Alessandro Vespignani
TI  - Estimating the spreading and dominance of SARS-CoV-2 VOC 202012/01 (lineage B.1.1.7) across Europe
AID  - 10.1101/2021.02.22.21252235
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.22.21252235
4099  - http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252235.short
4100  - http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252235.full
AB  - We develop a two strain, age-structured, compartmental model to assess the spreading potential of the B.1.1.7 variant across several European metropolitan areas and countries. The model accounts for B.1.1.7 introductions from the UK and different locations, as well as local mitigation policies in the time period 2020/09 − 2021/02. In the case of an increase of transmissibility of 50%, the B.1.1.7 variant has the potential to become dominant in all investigated areas by the end of March 2021.Competing Interest StatementA.V. reports grants and personal fees from Metabiota inc., outside the submitted work; M.C. reports grants from Metabiota inc., outside the submitted work. M.A. reports research funding from Seqirus; the funding is not related to COVID-19. No other relationships or activities that could appear to have influenced the submitted work.Funding StatementM.C., M.A., and A.V. acknowledge support from COVID Supplement CDC-HHS-6U01IP001137-01. M.C. and A.V. acknowledge support from Google Cloud and Google Cloud Research Credits program to fund this project. The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the funding agencies, the National Institutes of Health, or the U.S. Department of Health and Human Services.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSee supplementary information for all details